Sientra (NASDAQ:SIEN) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Sientra (NASDAQ:SIEN – Get Rating) in a report issued on Tuesday morning. The brokerage issued a sell rating on the medical instruments supplier’s stock.

A number of other research analysts have also recently commented on the company. Lake Street Capital dropped their price target on Sientra from $8.00 to $2.00 in a research report on Friday, September 16th. Craig Hallum dropped their price target on Sientra to $1.30 in a research report on Thursday, October 27th. Finally, William Blair cut Sientra from an outperform rating to a market perform rating in a report on Tuesday, October 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sientra presently has an average rating of Moderate Buy and an average price target of $5.19.

Sientra Price Performance

Shares of NASDAQ SIEN opened at $0.29 on Tuesday. Sientra has a one year low of $0.16 and a one year high of $4.43. The company has a debt-to-equity ratio of 7.28, a current ratio of 1.34 and a quick ratio of 0.70. The business’s fifty day moving average price is $0.41 and its 200-day moving average price is $0.72. The stock has a market capitalization of $18.82 million, a PE ratio of -0.26 and a beta of 1.51.

Institutional Trading of Sientra

Institutional investors and hedge funds have recently modified their holdings of the business. Advisor Group Holdings Inc. increased its position in shares of Sientra by 230.9% during the 1st quarter. Advisor Group Holdings Inc. now owns 11,930 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 8,325 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of Sientra by 57.7% during the 1st quarter. GSA Capital Partners LLP now owns 464,180 shares of the medical instruments supplier’s stock valued at $1,030,000 after purchasing an additional 169,799 shares during the last quarter. First Eagle Investment Management LLC increased its position in shares of Sientra by 93.4% during the 1st quarter. First Eagle Investment Management LLC now owns 490,809 shares of the medical instruments supplier’s stock valued at $1,090,000 after purchasing an additional 236,978 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Sientra by 65.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 203,809 shares of the medical instruments supplier’s stock valued at $452,000 after purchasing an additional 80,409 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Sientra during the 1st quarter worth approximately $68,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Sientra Company Profile

(Get Rating)

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.